| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 121.33B | 119.01B | 104.78B | 97.34B | 97.97B | 80.99B |
| Gross Profit | 57.23B | 56.19B | 48.83B | 42.79B | 42.87B | 34.87B |
| EBITDA | 24.86B | 24.94B | 21.73B | 23.75B | 25.20B | 21.08B |
| Net Income | 10.81B | 10.78B | 8.65B | 11.40B | 11.80B | 9.53B |
Balance Sheet | ||||||
| Total Assets | 187.61B | 192.02B | 212.75B | 187.26B | 189.27B | 179.00B |
| Cash, Cash Equivalents and Short-Term Investments | 36.54B | 44.90B | 58.58B | 47.12B | 51.56B | 54.70B |
| Total Debt | 62.16B | 64.52B | 86.72B | 71.50B | 78.15B | 81.22B |
| Total Liabilities | 87.64B | 89.04B | 112.35B | 94.53B | 103.81B | 102.51B |
| Stockholders Equity | 99.96B | 102.97B | 100.39B | 92.73B | 85.46B | 76.14B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 17.40B | 2.41B | 10.33B | 7.96B | 5.24B |
| Operating Cash Flow | 0.00 | 23.71B | 21.22B | 22.74B | 18.31B | 16.31B |
| Investing Cash Flow | 0.00 | -8.31B | -21.07B | -13.16B | -11.26B | -11.60B |
| Financing Cash Flow | 0.00 | -29.22B | 8.95B | -13.94B | -11.28B | 19.75B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥619.65B | 39.14 | ― | 3.26% | 11.78% | 8.98% | |
69 Neutral | ¥2.72T | 15.09 | 10.44% | 1.52% | 9.81% | 32.64% | |
68 Neutral | ¥466.36B | 13.77 | 13.71% | 3.38% | 0.29% | 27.84% | |
65 Neutral | ¥419.23B | 12.96 | 8.14% | 2.61% | -1.45% | ― | |
64 Neutral | ¥846.59B | -52.21 | -1.15% | 3.49% | -6.83% | -123.67% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ¥930.53B | 52.39 | 2.02% | 3.82% | -4.63% | -65.11% |
Taiyo Holdings has announced a set of senior personnel changes across its pharmaceutical and digital operations, resolved at a board meeting on February 4, 2026 and scheduled to take effect on April 1, 2026 following any necessary subsidiary procedures. The reshuffle primarily affects roles at Taiyo Pharma, funlead corp., and Taiyo Pharma Tech, and involves reallocation of responsibilities among senior corporate executive officers, including positions such as Chief Digital Officer and executive oversight of the information systems department, signaling an effort to strengthen management structure and coordination across its pharma and digital businesses within the group.
The most recent analyst rating on (JP:4626) stock is a Buy with a Yen5578.00 price target. To see the full list of analyst forecasts on Taiyo Holdings Co., Ltd. stock, see the JP:4626 Stock Forecast page.
In its FY2026/3 third-quarter consolidated financial result digest, Taiyo Holdings Co., Ltd. outlined the structure of its diversified operations across Electronics, Medical and Pharmaceuticals, and ICT and Sustainability, underscoring a portfolio that spans key growth areas such as PCB-related chemicals, pharmaceutical manufacturing and ICT and energy-related businesses. While the release focuses on segment definitions rather than specific figures, it highlights the company’s strategic positioning in both advanced manufacturing and healthcare, suggesting a business model designed to balance cyclical electronics demand with more stable medical and sustainability-driven revenue streams.
The most recent analyst rating on (JP:4626) stock is a Buy with a Yen5578.00 price target. To see the full list of analyst forecasts on Taiyo Holdings Co., Ltd. stock, see the JP:4626 Stock Forecast page.
Taiyo Holdings has revised upward its full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, after stronger-than-expected third-quarter performance in its Electronics business, particularly driven by robust demand for semiconductor package products and rigid board materials in China. The company now projects net sales of ¥133.0 billion and operating income of ¥29.6 billion, representing increases of 3.3% and 10.0%, respectively, over its previous forecast, with profit attributable to owners of parent raised to ¥20.1 billion and higher earnings per share. Segment data show that the upgrades are concentrated in the Electronics division, while forecasts for the Medical & Pharmaceuticals and ICT & Sustainability businesses, as well as the dividend outlook, remain unchanged, signaling that the current earnings momentum is largely electronics-driven and tied to semiconductor-related demand.
The most recent analyst rating on (JP:4626) stock is a Buy with a Yen5578.00 price target. To see the full list of analyst forecasts on Taiyo Holdings Co., Ltd. stock, see the JP:4626 Stock Forecast page.
Taiyo Holdings reported strong results for the nine months ended December 31, 2025, with net sales rising 14.4% year on year to ¥103.7 billion and profit attributable to owners of parent up 34.6% to ¥17.4 billion, lifting basic earnings per share to ¥156.93 on a post-split basis. The company’s equity ratio improved to 55.5% and net assets per share increased, underscoring a solid financial position, while the firm implemented a two-for-one stock split effective December 1, 2025 and maintained generous dividend plans, signaling confidence in earnings sustainability. Reflecting this momentum, Taiyo raised its full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, now projecting double-digit growth in sales and operating income and an 86.5% jump in full-year profit attributable to owners of parent to ¥20.1 billion, a move that highlights management’s positive outlook amid resilient demand in its core electronics-related markets.
The most recent analyst rating on (JP:4626) stock is a Buy with a Yen5578.00 price target. To see the full list of analyst forecasts on Taiyo Holdings Co., Ltd. stock, see the JP:4626 Stock Forecast page.
Taiyo Holdings Co., Ltd. has announced the resignation of Managing Executive Officer Naohiro Arata, effective December 19, 2025, after an internal probe with external experts found he had submitted inappropriate entertainment expense claims and received improper reimbursements; Arata has acknowledged the misconduct, fully refunded the amounts, and also stepped down as a director of subsidiary Taiyo Ink Mfg. Co., Ltd. In response, the company has tightened its expense review procedures, committed to further strengthening internal controls, and its president and representative director, Hitoshi Saito, will voluntarily return 10% of his monthly base salary for three months starting December 2025 as a gesture of accountability, signaling an effort to contain governance risks and reassure stakeholders about compliance and oversight standards.
The most recent analyst rating on (JP:4626) stock is a Buy with a Yen9789.00 price target. To see the full list of analyst forecasts on Taiyo Holdings Co., Ltd. stock, see the JP:4626 Stock Forecast page.
Taiyo Holdings announced a series of senior personnel changes, effective December 19, 2025 and January 1, 2026, including adjustments to executive officer roles overseeing production, digital strategy, finance, internal audit, human resources, and compliance across its electronics and pharmaceutical subsidiaries. In parallel, the company will transfer its Global Plants Initiative to Taiyo Ink Mfg. Co., Ltd. from the start of 2026, a move aimed at refining its management structure and consolidating global manufacturing functions under the core ink business, which may streamline governance, clarify accountability across group companies, and support more focused oversight of production and overseas plant management.
The most recent analyst rating on (JP:4626) stock is a Buy with a Yen9789.00 price target. To see the full list of analyst forecasts on Taiyo Holdings Co., Ltd. stock, see the JP:4626 Stock Forecast page.